ORGANOGENESIS HOLDINGS INC. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price
ORGANOGENESIS HOLDINGS INC. (ORGO) had Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price of $2.51 per share as of 2023-09-30, per its 10-Q filed 2023-11-09.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice · last filed 2023-11-09
- 2023-09-30: Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price $2.51.
- 2023-06-30: Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price $2.51.
- 2023-03-31: Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price $2.51.
- 2022-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price $8.03.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price as first filed |
|---|---|---|
| 2023-09-30 | $2.51 10-Q · filed 2023-11-09 | |
| 2023-06-30 | $2.51 10-Q · filed 2023-08-09 | |
| 2023-03-31 | $2.51 10-Q · filed 2023-05-10 | |
| 2022-12-31 | $8.03 10-K · filed 2023-03-01 | |
| 2022-09-30 | $8.03 10-Q · filed 2023-11-09 | |
| 2022-06-30 | $8.03 10-Q · filed 2023-08-09 | |
| 2022-03-31 | $8.03 10-Q · filed 2023-05-10 | $13.54 10-Q · filed 2022-05-10 |
| 2021-12-31 | $13.57 10-K · filed 2023-03-01 | |
| 2021-09-30 | $13.57 10-Q · filed 2022-11-09 | |
| 2021-06-30 | $13.54 10-Q · filed 2022-08-09 | |
| 2021-03-31 | $8.03 10-Q · filed 2022-05-10 | $13.54 10-Q · filed 2021-05-11 |
| 2020-12-31 | $4.04 10-K · filed 2022-03-01 | |
| 2020-09-30 | $4.04 10-Q · filed 2021-11-09 | |
| 2020-06-30 | $4.04 10-Q · filed 2021-08-09 | |
| 2019-12-31 | $7.08 10-K · filed 2021-03-16 | |
| 2019-09-30 | $7.08 10-Q · filed 2020-11-09 | |
| 2019-06-30 | $7.08 10-Q · filed 2019-08-09 | |
| 2018-12-31 | $5.99 10-K · filed 2020-03-09 | |
| 2018-09-30 | $5.40 10-Q · filed 2019-11-12 | |
| 2018-06-30 | $5.40 10-Q · filed 2019-08-09 | |
| 2018-03-31 | $5.99 10-Q · filed 2019-05-10 | |
| 2017-12-31 | $3.45 10-K · filed 2019-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 | |
| LIFECORE BIOMEDICAL, INC. DE (LFCR) | United States | $0.163B | -8.50 |